Tobam Sells 31,663 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Tobam decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 113,757 shares of the biotechnology company's stock after selling 31,663 shares during the period. United Therapeutics comprises 2.2% of Tobam's portfolio, making the stock its 18th biggest holding. Tobam owned about 0.24% of United Therapeutics worth $25,014,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of UTHR. Nordea Investment Management AB increased its holdings in shares of United Therapeutics by 155.2% in the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company's stock valued at $8,427,000 after purchasing an additional 23,532 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company's stock worth $20,617,000 after acquiring an additional 33,338 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of United Therapeutics by 4.9% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company's stock worth $520,000 after acquiring an additional 107 shares during the last quarter. DnB Asset Management AS acquired a new position in shares of United Therapeutics during the third quarter valued at $3,340,000. Finally, Vinva Investment Management Ltd boosted its holdings in United Therapeutics by 362.4% in the third quarter. Vinva Investment Management Ltd now owns 5,433 shares of the biotechnology company's stock valued at $1,228,000 after acquiring an additional 4,258 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Up 0.0 %

Shares of UTHR traded up $0.08 during mid-day trading on Tuesday, hitting $237.04. 399,157 shares of the company's stock were exchanged, compared to its average volume of 430,041. The company has a 50-day simple moving average of $228.15 and a 200 day simple moving average of $228.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The company has a market cap of $11.16 billion, a PE ratio of 11.95 and a beta of 0.52. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company's revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.67 EPS. On average, research analysts forecast that United Therapeutics Co. will post 23.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Finally, Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $294.40.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 5,060 shares of United Therapeutics stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $237.52, for a total transaction of $1,201,851.20. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,877.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $218.72, for a total value of $1,312,320.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $8,004,933.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 5,060 shares of the firm's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $237.52, for a total transaction of $1,201,851.20. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,877.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,190 shares of company stock worth $26,027,259. Corporate insiders own 12.50% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.